Back to top

Why You Shouldn't Bet Against Goldman Sachs (GS) Stock

Read MoreHide Full Article

One stock that might be an intriguing choice for investors right now is The Goldman Sachs Group, Inc. (GS - Free Report) . This is because this security in the Financial - Investment Bank space is seeing solid earnings estimate revision activity and is in great company from a Zacks Industry Rank perspective.

This is important because, often times, a rising tide will lift all boats in an industry, as there can be broad trends taking place in a segment that are boosting securities across the board. This is arguably taking place in the Financial - Investment Bank space as it currently has a Zacks Industry Rank of 45 out of more than 250 industries, suggesting it is well-positioned from this perspective, especially when compared to other segments out there.

Meanwhile, Goldman Sachs is actually looking pretty good on its own too. The firm has seen solid earnings estimate revision activity over the past month, suggesting analysts are becoming a bit more bullish on the firm’s prospects in both the short and long term.

The Goldman Sachs Group, Inc. Price and Consensus

In fact, over the past month, current quarter estimates have risen from $5.31 per share to $5.80 per share, while current year estimates have risen from $23.22 per share to $24.98 per share. This has helped GS to earn a Zacks Rank #2 (Buy), further underscoring the company’s solid position.  You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.

So, if you are looking for a decent pick in a strong industry, consider Goldman Sachs. Not only is its industry currently in the top third, but it is seeing solid estimate revisions as of late, suggesting it could be a very interesting choice for investors seeking a name in this great industry segment.

5 Medical Stocks to Buy Now

Zacks names 5 companies poised to ride a medical breakthrough that is targeting cures for leukemia, AIDS, muscular dystrophy, hemophilia, and other conditions.

New products in this field are already generating substantial revenue and even more wondrous treatments are in the pipeline. Early investors could realize exceptional profits.

Click here to see the 5 stocks >>




In-Depth Zacks Research for the Tickers Above


Normally $25 each - click below to receive one report FREE:


The Goldman Sachs Group, Inc. (GS) - free report >>

More from Zacks Tale of the Tape

You May Like